T1	Participants 50 118	hyperglycemic patients with non-ST elevation acute coronary syndrome
T2	Participants 282 349	in patients with diabetes receiving standard treatment for diabetes
T3	Participants 691 761	patients with diabetes and A1C of >or=8-10% at randomization (n = 171)
T4	Participants 862 888	placebo-adjusted (n = 182)
T5	Participants 1417 1613	Ranolazine, compared with placebo, was not associated with serious hypoglycemic events, associated with significant changes in concurrent antidiabetic therapy, or dependent on a history of angina.
T6	Participants 1709 1776	patients with cardiovascular disease and poorly controlled diabetes
